AlphaQuest LLC Has $1.59 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

AlphaQuest LLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,833 shares of the company’s stock after buying an additional 963 shares during the period. AlphaQuest LLC’s holdings in IDEXX Laboratories were worth $1,585,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the third quarter valued at about $25,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $30,000. Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories during the third quarter valued at about $37,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $31,000. Finally, Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $430.12 on Monday. The firm has a market cap of $34.98 billion, a price-to-earnings ratio of 40.31, a PEG ratio of 3.41 and a beta of 1.39. The company has a 50 day moving average of $437.37 and a 200-day moving average of $449.09. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $562.25.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.